Pegylated Interferon-α2b
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Aug 11, 2020 → Jun 21, 2021
NCT ID
NCT04480138About Pegylated Interferon-α2b
Pegylated Interferon-α2b is a phase 2 stage product being developed by Zydus Lifesciences for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04480138. Target conditions include Covid19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04480138 | Phase 2 | Terminated |
Competing Products
20 competing products in Covid19